<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799639</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-201-01</org_study_id>
    <nct_id>NCT04799639</nct_id>
  </id_info>
  <brief_title>Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer</brief_title>
  <official_title>Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of Sindilimab combined with Paclitaxel and Cisplatin in&#xD;
      neoadjuvant chemotherapy for Locally Advanced Cervical Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 47 patients will be enrolled in this study. After screening, patients will receive&#xD;
      intravenous drip of standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3&#xD;
      cycles. CT/MR of chest, upper and lower abdomen and pelvic MR will be performed before&#xD;
      treatment and 2 weeks after the 3rd cycle chemotherapy. The objective response rate (ORR) (CR&#xD;
      + PR) is evaluated by comparing with baseline based on RECISTv1.1. Radical surgery will be&#xD;
      performed after NACT. According to the postoperative pathological results, the pathological&#xD;
      complete remission rate (pCR) will be evaluated. The adverse events will be continuously&#xD;
      monitored during treatment until 30 days after chemotherapy. Toxic adverse events is&#xD;
      evaluated according to NCI-CTCAEv5.0 criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>patients will receive intravenous drip of standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete remission rate (pCR) rate</measure>
    <time_frame>3 months</time_frame>
    <description>According to the postoperative pathological results, the pathological complete remission rate (pCR) will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR) (CR + PR)</measure>
    <time_frame>3 months</time_frame>
    <description>The objective response rate (ORR) (CR + PR) is evaluated by comparing with baseline based on RECISTv1.1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Programmed Cell Death 1 Receptor / Antagonists &amp; Inhibitors</condition>
  <condition>Neoadjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>paclitaxel + cisplantin + Sindilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles paclitaxel 150mg/m2，ivdrip,&gt;3 hours cisplantin 70mg/m2，ivdrip，&gt;1 hours Sindilimab 200mg，ivdrip, &gt;0.5 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sindilimab +paclitaxel+ cisplantin</intervention_name>
    <description>standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles</description>
    <arm_group_label>paclitaxel + cisplantin + Sindilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 to 65 years with primary cervical cancer;&#xD;
&#xD;
          2. Clinical diagnosis of cervical cancer stage IB3 or IIA2 (FIGO stage, 2018). The stage&#xD;
             was determined by two associate senior physicians or above after examining the&#xD;
             patients;&#xD;
&#xD;
          3. no distant organ metastasis, and the short diameter of retroperitoneal lymph nodes was&#xD;
             less than 1 cm;&#xD;
&#xD;
          4. according to the RECIST version 1.1 criteria, the measurable lesion of the cervix&#xD;
             assessed by imaging was &gt; 3.5 cm;&#xD;
&#xD;
          5. histological types includes cervical squamous cell carcinoma, adenocarcinoma or&#xD;
             adenosquamous carcinoma;&#xD;
&#xD;
          6. no radiotherapy, chemotherapy or targeted therapy before;&#xD;
&#xD;
          7. the expected survival time was greater than 3 months;&#xD;
&#xD;
          8. the ECOG score of the Eastern Cooperative Oncology Group was 0 - 1;&#xD;
&#xD;
          9. the function of important organs met the requirements of surgery, chemotherapy and&#xD;
             radiotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other malignant tumors;&#xD;
&#xD;
          2. Patients is pregnancy or in perinatal period;&#xD;
&#xD;
          3. Patients with myocardial infarction or stroke, or unstable angina pectoris,&#xD;
             decompensated heart failure, or deep venous thrombosis;&#xD;
&#xD;
          4. Patients with NCI-CTCAE 5.0 ≥ grade 2 arrhythmia, any grade of atrial fibrillation, or&#xD;
             clinically significant supraventricular or ventricular arrhythmia requiring treatment&#xD;
             or intervention;&#xD;
&#xD;
          5. Patients with active pneumonia: hepatitis patients with progressive loss of appetite,&#xD;
             general weakness, nausea, acid reflux, anorexia, abdominal distension and other&#xD;
             clinical manifestations, abnormal liver function and jaundice such as yellow eyes,&#xD;
             yellow urine and other clinical symptoms;&#xD;
&#xD;
          6. Patients with liver dysfunction (aspartate/alanine aminotransferase &gt; 2.5 times the&#xD;
             upper limit of the standard);&#xD;
&#xD;
          7. Patients with renal insufficiency (serum creatinine &gt; 2 times the upper limit of the&#xD;
             standard);&#xD;
&#xD;
          8. History of chronic lung disease with restrictive respiratory dysfunction;&#xD;
&#xD;
          9. History of important organ transplantation, history of immune diseases;&#xD;
&#xD;
         10. History of severe mental illness, History of cerebral dysfunction;&#xD;
&#xD;
         11. history of drug abuse or drug use;&#xD;
&#xD;
         12. patients are using immunosuppressive agents, or systemic hormone therapy to achieve&#xD;
             the purpose of immunosuppression (dose &gt; 10 mg prednisone or other effective&#xD;
             hormones), and continue to use 2 weeks before enrollment;&#xD;
&#xD;
         13. coagulation abnormalities (INR &gt; 2.0, PT &gt; 16s), with bleeding tendency or are&#xD;
             receiving thrombolytic or anticoagulant therapy, allowing prophylactic use of low-dose&#xD;
             aspirin,Low molecular weight heparin;&#xD;
&#xD;
         14. Congenital or acquired immunodeficiency (such as HIV infection);&#xD;
&#xD;
         15. Received live vaccine within 30 days before the first dose;&#xD;
&#xD;
         16. Unable or unwilling to sign the informed consent form or comply with the study&#xD;
             requirements;&#xD;
&#xD;
         17. Have a history, disease or laboratory abnormalities that may interfere with the test&#xD;
             results or prevent the subject from participating in the study, or the investigator&#xD;
             believes that participating in the study is not in the best benefit of the subject.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihong Liu, Ph D</last_name>
    <phone>+86‭13826299236</phone>
    <email>liujh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Wan, MD</last_name>
    <phone>+86‭13824444081‬</phone>
    <email>wanting@sysucc.org.cn</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

